Möchten Sie immer auf dem neuesten Stand bleiben?

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data in Pediatric Dermatology

Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

Castle announced the publication of a validation study in the Journal of the American Academy of Dermatology for its AdvanceAD-Tx test.

SHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of novel multispecific antibodies, today announced the...

58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a...

Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity First-in-class, oral PKM2 modulator, SYX-5219, has the...

Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Plans For Those With Chronic Inflammatory Skin Conditions

Preclinical in vivo efficacy data (PoC) in atopic dermatitis of disease-modifying therapy; positive patent opinion from the EU Patent Office

Dublin, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The "Dermatology Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The dermatology market is undergoing a...

Oxford, UK and Boston, MA – January 6, 2026 – Sitryx Therapeutics (“Sitryx” or “the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in...